Role of Microvascular Surgery in Today's Surgical Practice

1. Historical Foundation and Technical Basis

2. Reconstructive Surgery - Head and Neck

3. Breast Reconstruction

"The DIEP has totally changed the approach to breast reconstruction, often supplanting the TRAM flap." - Mulholland & Greenfield's Surgery, 7e, p. 6012

4. Replantation Surgery

1. Bony fixation (K-wires, plate)
2. Extensor tendon repair
3. Flexor tendon repair
4. Arterial anastomosis (under microscope, 9-0 nylon)
5. Nerve repair (epineural or fascicular)
6. Venous anastomosis (2 veins recommended per artery)
7. Skin closure

• Thumb amputations (highest priority - provides 40% of hand function)
• Multiple digit amputations
• Amputations in children (high plasticity, excellent outcomes)
• Transmetacarpal and wrist-level amputations
• Single-digit amputations distal to the FDS insertion

5. Digit and Thumb Reconstruction - Toe-to-Hand Transfer

6. Lower Extremity Limb Salvage

"Lower extremity limb salvage is much more predictable using microvascular free flaps. Fasciocutaneous perforator free flaps have largely replaced musculocutaneous and muscle flaps. The most commonly used are the ALT flap, DIEP, and the radial forearm free flap." - Mulholland & Greenfield's Surgery, 7e, p. 6012

7. Peripheral Nerve Surgery

• Epineural repair - alignment and suture of nerve sheath for sharp transections
• Grouped fascicular repair - individual fascicle identification and repair for larger nerves
• Nerve grafting - using sural nerve as a conduit to bridge gaps >2 cm; interfascicular nerve grafting (Millesi technique)
• Nerve conduits - collagen or synthetic tubes for digital nerve gaps <3 cm

8. Lymphedema Surgery - Supermicrosurgery

1. Lymphaticovenous anastomosis (LVA) - connects lymphatic channels to venules under the skin, creating a bypass for obstructed lymphatic flow. Performed with 11-0 to 12-0 suture.
2. Vascularized lymph node transfer (VLNT) - transfers a lymph node-bearing tissue flap (cervical, inguinal, or omental) to the affected limb to restore lymphatic drainage.

"Supermicrosurgery, a technique of dissection and anastomosis of small vessels ranging from 0.3 to 0.8 mm... has revolutionized the fields of lymphedema treatment and soft tissue reconstruction." - Mulholland & Greenfield's Surgery, 7e, p. 6011

9. Vascularized Composite Allotransplantation (VCA)

• Hand and upper extremity transplantation (>100 cases performed worldwide)
• Face transplantation (>40 cases performed globally)

10. Emerging Frontiers

11. Anesthetic Considerations

• General or regional anesthesia - regional techniques preferred for sympathectomy effect (maximizing vasodilation)
• Normothermia maintained throughout to prevent vasospasm
• Permissive hemodilution to hematocrit 27-30% - reduces viscosity and improves flow through anastomosis
• Fluid replacement at 3.5-6 mL/kg/hr to maintain adequate perfusion
• Vasopressors used cautiously - must be coordinated with the surgical team; potential for flap ischemia
• Postoperative anticoagulation - unfractionated or low-molecular-weight heparin to prevent graft thrombosis
• Barash Clinical Anesthesia, 9e, p. 4390

Summary

Recent Advances in ERCP

1. Digital Single-Operator Cholangioscopy (DSOC)

• 4-way tip deflection (up/down/left/right) allowing complete ductal navigation
• High-definition digital imaging (vs. fiber optic pixelation of older systems) providing 4x improvement in image quality
• 1.2 mm working channel for biopsy forceps, electrohydraulic lithotripsy (EHL) probes, or laser probes
• Can be used by a single operator - the prior 2-person system was cumbersome and limited adoption

• Indeterminate biliary strictures: Targeted biopsies under direct vision achieve overall diagnostic accuracy of 85-95% for cholangiocarcinoma vs. 55-90% for conventional ERCP brush cytology alone - Bailey & Love's Surgery, 28e
• Difficult CBD stones: Cholangioscopy-guided EHL or holmium laser lithotripsy for large/impacted stones failing standard balloon/basket clearance - Sabiston Textbook of Surgery, 11e
• Post-transplant anastomotic strictures: A 2025 clinical trial (SPYPASS-2 study, PMID: 39557203) showed DSOC successfully managed difficult anastomotic strictures in living-donor liver transplant recipients after failed standard ERCP
• Proximally migrated stent retrieval: DSOC as a rescue technique when conventional ERCP extraction fails
• Primary sclerosing cholangitis (PSC): Surveillance biopsies of dominant strictures to detect superimposed cholangiocarcinoma - Sleisenger & Fordtran, 10e

2. Advanced Imaging Modalities at ERCP

A. Intraductal Ultrasound (IDUS)

• Criteria for malignancy: disrupted triple-layer wall architecture, eccentric thickening, hypoechoic mass with irregular margins, vascular invasion
• Sensitivity 80-90%, specificity 83% for malignant strictures
• Improves ERCP accuracy from 58% to 83% for stricture characterization
• Limitation: provides imaging only - no tissue; fragile probe; capital equipment requirement - Clinical GI Endoscopy, Expert Consult, 3e

B. Optical Coherence Tomography (OCT)

• Differentiates normal triple-layer ductal architecture from disrupted malignant architecture
• Can visualize tumor neovascularization as large non-reflective areas
• When combined with standard tissue sampling, sensitivity for malignancy rises to 84% - Clinical GI Endoscopy, Expert Consult, 3e

C. Probe-Based Confocal Laser Endomicroscopy (pCLE)

• Miami Classification criteria: thick white bands (>20 µm), dark clumps, epithelial structures = malignancy vs. thin white bands, dark granules = benign/inflammation
• Prospective multicenter study (89 patients) showed excellent sensitivity for malignancy
• Paris Classification refined criteria specifically for PSC-related strictures
• A key advantage: immediate "optical biopsy" result intraoperatively - Clinical GI Endoscopy, Expert Consult, 3e

D. Fluorescence In Situ Hybridization (FISH) on Brush Cytology

3. Cannulation Techniques - World Endoscopy Organization 2025 Guidelines

• Guidewire-assisted cannulation preferred over contrast injection technique - reduces PEP risk
• Pancreatic duct (PD) stenting after inadvertent PD cannulation
• Limit cannulation attempts; after 5 failed attempts consider advanced techniques

1. Double-guidewire technique (DGT) - once a wire is placed in the PD inadvertently, a second wire guides biliary cannulation
2. Pancreatic duct guidewire-assisted cannulation - uses the PD wire as a landmark
3. Needle-knife precut sphincterotomy - fistulotomy or transpancreatic approach when standard techniques fail
4. EUS-guided rendezvous - when endoscopic access fails entirely
5. Percutaneous transhepatic approach - last resort before considering surgery

• Periampullary diverticula (Lemmel syndrome)
• Duodenal stenosis from cancer
• Billroth II anatomy

4. Prevention of Post-ERCP Pancreatitis (PEP) - Updated 2023 Guidelines

• Sleisenger & Fordtran, 10e; Clinical Practice Guidelines PEP 2023

5. ERCP in Surgically Altered Anatomy

• EDGE is now endorsed by ASGE guidelines as the preferred approach for RYGB anatomy (PMID: 39078360)
• EDGE uses a lumen-apposing metal stent (LAMS) placed between the gastric pouch and excluded stomach under EUS guidance, then standard duodenoscope is passed through the stent

6. EUS-Guided Biliary Drainage (EUS-BD) - ERCP Alternative

EUS-Choledochoduodenostomy (EUS-CDS)

• For distal malignant biliary obstruction with normal anatomy
• LAMS or biliary metal stent placed between CBD and duodenum under EUS guidance
• Technical success >90% in expert centers
• Comparable to PTBD with better quality of life

EUS-Hepaticogastrostomy (EUS-HGS)

• For hilar obstruction or when duodenum is not accessible
• Stent placed between left hepatic duct and stomach
• Used when CDS not feasible

EUS-Guided Rendezvous (EUS-RV)

• Wire passed via EUS from CBD through papilla, then ERCP completed antegradely
• Particularly valuable in benign disease (avoids stenting bile duct transmurally)
• A 2026 retrospective study (PMID: 42301440) shows excellent outcomes in both benign and malignant settings

EUS-Guided Gallbladder Drainage (EUS-GBD)

• LAMS-based cystoenterostomy for acute cholecystitis in non-surgical patients
• Now preferred over percutaneous cholecystostomy by ASGE guidelines

7. Stenting Advances

• Current Surgical Therapy, 14e; Fischer's Mastery of Surgery, 8e

8. Artificial Intelligence in ERCP

• Biliary stricture characterization: Deep learning analysis of cholangioscopy images - multicenter study showed AI detection of malignant bile duct stenosis on ERCP fluoroscopy (PMID: 39675349)
• AI + DSOC combination: Systematic review (PMID: 39998988) showed AI augmentation of digital cholangioscopy improves diagnostic accuracy for indeterminate strictures
• PEP risk prediction: ML models to identify high-risk patients pre-procedurally and guide prophylaxis decisions
• Cannulation assistance: AI guidance for optimal papillary approach and technique selection
• Radiation dose reduction: AI-guided fluoroscopy optimization

9. Choledocholithiasis - Advanced Stone Clearance

• Cholangioscopy-directed electrohydraulic lithotripsy (EHL): Bipolar spark-gap probe fired under direct cholangioscopic vision - highly effective
• Holmium laser lithotripsy via SpyGlass: Fragmentation of stones under direct vision; high success rates (>90%) for difficult stones
• Extracorporeal shock wave lithotripsy (ESWL) combined with ERCP remains an option for very large stones
• Adjunct to ERCP/choledochoscopy via PTC or intraoperative route for high peripheral stones - Sabiston Textbook of Surgery, 11e

10. Quality Metrics in ERCP

Summary of Key Advances

Artificial Intelligence in Surgery

1. Conceptual Framework: What is AI in Surgery?

2. Preoperative Applications

A. Diagnostic Imaging and 3D Reconstruction

• Applied in hepatic surgery (delineating vascular and biliary anatomy before hepatectomy)
• Orthopedic trauma (fracture planning, implant sizing)
• Vascular surgery (endovascular stent-graft sizing)
• Colorectal surgery (fistula mapping, complex pelvic anatomy)
• Oncology (sentinel lymph node identification from SPECT-CT, as shown in tongue cancer planning)

B. Preoperative Risk Prediction

• Processes >37 million clinical encounters; extracts 194 clinical features
• Predicts 13 postoperative complications and 30-day mortality
• Uses Random Forest, XGBoost, and LASSO algorithms
• LASSO model AUC of 0.79 vs. 0.67 for ACS NSQIP for 30-day mortality
• Available as an online risk calculator for institutional use

• Integrated directly into the EHR; calculates risk in real time at the point of care
• Predicts 8 postoperative complications (AKI, sepsis, VTE, ICU >48 hrs, prolonged ventilation, wound, neurologic, cardiovascular) - AUCs 0.82-0.94
• Enhanced version "MySurgeryRisk Postop" incorporates intraoperative data, improving mortality prediction by 11.2%

• Emergency surgery need for ICU (smartphone-accessible tool)
• Postoperative delirium (ML systematic review and meta-analysis, PMID: 41057784, 2025 - showed high diagnostic performance)
• Cardiac surgery: Postoperative AF, acute kidney injury prediction
• Perioperative problems - comprehensive AI review (PMID: 39212575)
• Sabiston Textbook of Surgery, 11e

C. NLP for Workflow and Referral Management

• Screen and prioritize referrals
• Auto-extract diagnosis codes
• Generate pre-procedural consent documentation
• Flag missing preoperative investigations

3. Intraoperative Applications

A. Computer Vision - Anatomical Structure Recognition

• Identify the critical view of safety in real time - recognizing the cystic duct and common bile duct
• Alert the surgeon when the anatomy is unclear or when the "critical view" has not been achieved
• Going forward, a surgeon will be able to highlight an unclear anatomical area on screen and AI will identify structures within it

"A particular focus of research has been on laparoscopic cholecystectomy, as a bile duct injury can confer significant morbidity in what is often considered a routine procedure." - Fischer's Mastery of Surgery, 8e, p. 821

• Colorectal surgery - identifying ureter, inferior mesenteric vessels
• Thyroid surgery - recurrent laryngeal nerve identification
• Oncologic surgery - real-time tumor margin assessment ("optical biopsy")

B. Surgical Phase Recognition

• Automatic display of reference material or step-by-step guides at the appropriate phase
• Instrument preparedness alerts
• Integration with OR scheduling and instrument management
• Foundation for autonomous surgery - phase recognition is the first step toward a robot understanding and executing surgical tasks independently - Fischer's Mastery of Surgery, 8e

C. Intraoperative Tissue Analysis and Perfusion

• Hyperspectral imaging + AI: Simultaneously measures tissue oxygenation and blood flow at the tissue surface - relevant for anastomotic perfusion assessment in bowel surgery, flap viability
• Confocal laser endomicroscopy (pCLE) + AI: Real-time optical biopsy of biliary strictures and GI lesions
• Fluorescence imaging + AI: AI-guided ICG perfusion mapping to assess anastomotic blood supply and guide extent of resection
• AI-assisted frozen section analysis: Deep learning classification of tissue samples to reduce time and human error in intraoperative pathology

D. Intraoperative Decision Support

• Bleeding risk alerts based on real-time hemodynamic trends
• Context-sensitive guidance based on operative phase
• Automated instrument tracking and usage analytics

4. Robotic Surgery and AI Integration

Key capabilities when AI + Robotics combine:

"The most credible short-range advances of AI consist in generating assistive systems that enhance perception, anticipate risks and standardize feedback while remaining under surgeon control... Long-term directions include emerging vision-language-action interfaces capable of programming task-specific support through natural language."

• 25% reduction in operative time vs. manual methods
• 30% decrease in intraoperative complications
• 40% improvement in surgical precision (targeting accuracy)
• 15% shorter patient recovery time
• 20% increase in surgeon workflow efficiency
• 10% reduction in healthcare costs per procedure

Robotic Platforms Beyond da Vinci

5. Surgical Performance Assessment and Training

JIGSAWS Dataset

• Kinematic data: Cartesian positions, velocities, orientations, gripper angles of robot arms
• Video data: Stereo endoscopic video of knot tying, suturing, needle passing
• Manual annotations: OSATS scores, surgical gesture labels

AI-Based Video Assessment

• CNNs classify surgeon skill level (novice/intermediate/expert) with 95-100% accuracy
• Improves OSATS scoring by 35% over prior algorithms
• Generates formative feedback via heatmaps showing which operative segments failed FLS criteria

• AI-generated metrics from robotic prostatectomy video predicted urinary continence outcomes better than patient/disease factors
• Provides individualized feedback that demonstrably improves performance

Virtual Reality Training + AI

• VR laparoscopic simulators with AI-personalized curricula adapt difficulty and provide instant feedback
• da Vinci SimNow robotic simulator: AI scoring system differentiates novice/expert; 83% of trainees reach mastery at median 7 hours of AI-guided practice
• iSurgeon (Heidelberg) uses augmented reality telestration - instructor hand movements overlaid on laparoscopic images in real time

6. Postoperative Applications

Surveillance and Early Warning Systems

• Continuous vital sign monitoring with ML anomaly detection to identify early deterioration (National Early Warning Score 2 enhanced by AI)
• ICU false alarm reduction: ML models reduce alarm fatigue by filtering non-actionable alerts
• Predictive models for anastomotic leak based on intraoperative and early postoperative data

Natural Language Processing for Documentation

• Automated operative note generation from structured robotic/laparoscopic data
• AI-assisted coding and billing from surgical reports
• Real-time discharge summary generation

Image Analysis for Wound and Pathology

• AI-powered wound assessment from smartphone photos (deep learning classifies healing vs. infected vs. dehisced wounds)
• Digital pathology: CNN-based analysis of surgical specimens improves lymph node yield and staging accuracy

7. Specialty-Specific Highlights

8. Limitations and Barriers to Adoption

Technical Limitations

1. "Black box" problem - Deep learning models do not explain their reasoning; this limits trust, validation, and regulatory acceptance
2. Training data quality - Healthcare datasets are unstandardized, fragmented, and in differing formats; large curated datasets are needed
3. Dataset bias - Ethnic minorities are systematically underrepresented in training data, creating models that perform worse for these groups
4. Generalizability - Models trained at one institution often fail to perform equivalently at others ("overfitting")
5. Temporal drift - Clinical practice changes; models trained on historical data may become outdated

Regulatory and Governance

• FDA approval for AI/ML surgical devices is increasing but still limited - most systems remain research tools
• A 2026 review identified FDA-approved AI devices in general surgery (Surgery, 2026) and orthopedics (JAAOS 2026) - regulatory framework still evolving
• Accountability: When an AI system contributes to a surgical error, legal liability is unresolved

Ethical Considerations

• Patient data privacy: Training large models requires patient-identifiable data; data governance frameworks are insufficient in most jurisdictions
• Informed consent: Patients may not realize AI systems are involved in their care
• Autonomy vs. safety: Fully autonomous surgical systems raise profound ethical questions about removing human judgment from irreversible actions

Practical Barriers

• High capital cost of AI-integrated robotic systems
• Surgeon resistance/skepticism and training requirements
• Integration with legacy hospital IT systems
• Cybersecurity vulnerabilities

9. The Road Ahead: Future Directions

"AI in surgery is a rapidly evolving and promising field for innovation, with its full potential reliant on enhanced collaboration across disciplines." - Li et al., Int J Surg 2025

Summary

PREOPERATIVE          INTRAOPERATIVE              POSTOPERATIVE
─────────────────     ─────────────────────────   ──────────────────────
• 3D reconstruction   • Anatomy detection (CV)    • Early warning systems
• Risk prediction     • Phase recognition         • Wound assessment
• NLP referral triage • Optical biopsy            • Pathology analysis
• Imaging AI          • AR image overlay          • Outcome surveillance
• Simulation training • Robotic kinematics + AI   • NLP documentation
                      • Autonomous task assist    • Readmission prediction

Recent Advances in Surgical Approach to Rectal Cancer

1. The Enduring Gold Standard: Total Mesorectal Excision (TME)

• R0 resection (microscopically negative CRM and distal margins)
• Complete mesorectal excision (intact specimen with no defects, no "waisting")
• Autonomic nerve preservation (hypogastric plexus, pelvic splanchnic nerves)
• Sphincter preservation wherever oncologically safe
• Minimizing functional morbidity - urinary, sexual, and bowel dysfunction

"There is general agreement that optimal surgical treatment involves TME with an R0 excision, regardless of approach (open, laparoscopic, or robotic)." - Fischer's Mastery of Surgery, 8e

2. Minimally Invasive Platforms: The Evidence Landscape (2024-2026)

A. Laparoscopic TME

• Operative benefits: Longer operative time, but less blood loss, faster bowel recovery, shorter hospital stay
• Oncologic equivalence: 5-year LR, DFS, and OS not significantly different
• Critical caveat: ALACART and Z6051 failed to demonstrate non-inferiority of laparoscopic resection for the composite oncologic endpoint (CRM positivity + completeness of TME + distal margin)
• Adoption remains low at <25% of US rectal cancer operations

B. Robotic TME (RoTME)

• Articulated EndoWrist instruments allowing distal stapling near the anorectal ring
• 3D stereoscopic HD vision improving anatomical dissection
• Motion scaling and tremor filtration
• Nerve-sparing precision - improved visualization of hypogastric nerves and pelvic plexus

• TaTME had significantly lower odds of non-complete mesorectal excision vs. laparoscopy (OR 0.60, p=0.02)
• Robotic TME also had significantly lower odds of non-complete mesorectal excision vs. laparoscopy (OR 0.68, p=0.02)
• TaTME had significantly lower positive CRM rate vs. laparoscopic (OR 0.36, p=0.02)
• Robotic TME retrieved significantly more lymph nodes than laparoscopy (MD +1.24)
• SUCRA ranking: TaTME ranked best for complete TME and negative CRM; RoTME ranked best for lymph node yield

C. Transanal TME (TaTME) - The Paradigm Shift from Below

1. Transanal platform (e.g., GelPOINT Path) placed in anal canal
2. Purse-string suture placed distal to tumor under direct vision - ensures accurate distal margin
3. Full-thickness entry into perirectal fat above the levators
4. "Bottom up" mesorectal dissection in correct TME planes under excellent distal visualization
5. Simultaneous or sequential abdominal team completes proximal dissection laparoscopically
6. Anastomosis: handsewn coloanal or circular-stapled using purse-string

• Superior visualization of distal rectum and correct TME planes in challenging anatomy
• Accurate assessment of distal resection margin under direct vision (no reliance on stapler "feel")
• Better sphincter preservation for very low tumors
• Less need for abdominal conversion

• 43 fewer 30-day major complications per 1,000 patients with TaTME vs. laparoscopic TME
• 34 fewer disease recurrences at 2 years per 1,000 patients with TaTME vs. laparoscopic TME
• No clinically important differences between TaTME and robotic TME - these two platforms are effectively equivalent for low/mid rectal cancer

• Operative time, hospital stay, blood loss: comparable
• Conversion: trend favoring TaTME
• Sphincter preservation: trend favoring TaTME
• R0 resection: trend favoring RoTME
• Overall, both platforms yield comparable perioperative and short-term oncological outcomes

• Norway imposed a national moratorium after reporting multifocal local recurrence in 2019 - attributed to CO₂ insufflation-related gas dissection into the TME plane causing tumor cell dissemination
• Subsequent international registry data (2025) has largely exonerated TaTME when performed by trained surgeons in expert centers
• Urethral injury remains a unique, serious TaTME-specific complication from distorted anterior anatomy - requires meticulous dissection and urethral awareness
• A structured training pathway (standardized 2-team approach, dedicated proctored cases) is mandatory

3. Local Excision - Transanal Platforms for Early Rectal Cancer

• T1, well/moderate differentiation
• No lymphovascular invasion, no perineural invasion
• Tumor <3 cm, <30% circumference
• Negative deep margin (≥1 mm)
• Low/mid rectum (accessible transanally)
• Pre-treatment MRI and ERUS to confirm cT1N0

• Fischer's Mastery of Surgery, 8e; Sabiston Textbook of Surgery, 11e

4. Organ Preservation: Watch-and-Wait (Non-Operative Management)

The OPRA Trial - Landmark Evidence

• Arm 1: Induction chemotherapy → CRT (INCT-CRT)
• Arm 2: CRT → Consolidation chemotherapy (CRT-CNCT)

• 5-year DFS: 71% (INCT-CRT) vs. 69% (CRT-CNCT) - equivalent survival
• TME-free survival: 39% (INCT-CRT) vs. 54% (CRT-CNCT) - consolidation chemotherapy after CRT leads to significantly higher organ preservation rate (p=0.012)
• 94% of tumor regrowths occurred within 2 years - surveillance protocols front-load follow-up intensity
• Patients who needed TME after regrowth in W&W had equivalent DFS (64%) to patients who went straight to TME after restaging

• CRT followed by consolidation chemotherapy (TNT sequencing) achieves higher organ preservation than induction-first approach
• Half of rectal cancer patients treated with TNT can avoid surgery long-term
• When regrowth occurs, salvage TME remains feasible with equivalent outcomes to primary surgery

Network Meta-Analysis (2025, PMID: 39945776)

• TME significantly superior to W&W and LE for 2-year local regrowth rate
• W&W and LE are non-inferior to TME for 3-year and 5-year overall survival
• Practical message: More local events in W&W/LE, but salvage surgery rescues survival - net long-term survival equivalent when properly managed

Patient Selection for Watch-and-Wait

• Endoscopy: Whitening/fibrosis at tumor site, no residual ulcer/mass
• MRI: mrTRG 1-2, no residual signal, lymph node regression
• Digital rectal exam: No palpable lesion

5. Total Neoadjuvant Therapy (TNT) - Redefining the Treatment Sequence

1. Induction: Chemotherapy (FOLFOX/CAPOX) → CRT → surgery/W&W
2. Consolidation: CRT → Chemotherapy → surgery/W&W (preferred for organ preservation per OPRA)

• Mulholland & Greenfield's Surgery, 7e

6. Immunotherapy for dMMR/MSI-H Rectal Cancer - Surgery Avoidance

• Dostarlimab (GARNET trial update): 100% clinical complete response in 12/12 patients with locally advanced dMMR rectal cancer treated with neoadjuvant dostarlimab alone - none required surgery or radiation
• Pembrolizumab for dMMR rectal cancer: Multiple series showing pCR rates approaching 60-100%

7. Extralevator APR (ELAPE) - Oncologic Optimization for T4 Low Rectal Cancer

• Standard APE creates a "waist" at the anorectal junction where the specimen narrows - the most common site of positive CRM
• ELAPE removes the entire levator ani complex en bloc with the specimen, creating a cylindrical specimen without the narrowing
• Perineal closure often requires plastic reconstruction (gluteal rotation flap, myocutaneous flap, biologic mesh) due to the larger perineal defect
• Perineal wound complication rates: 15-32% for SAPE and ELAPE, with higher rates after preoperative radiation
• Mulholland & Greenfield's Surgery, 7e

8. Functional Outcomes and Quality of Life - The New Co-Primary Endpoint

9. Emerging Platforms and Future Directions

Summary: Evolving Decision Framework

RECTAL CANCER DIAGNOSIS
         │
         ├── MSI-H/dMMR (~15%) → Immunotherapy (dostarlimab/pembrolizumab)
         │                         → cCR achieved → Watch-and-Wait
         │                         → Incomplete response → TME
         │
         ├── Stage I (T1-2N0) → Local excision (TEM/TAMIS) for T1
         │                    → TME for T2 (or selected T1 with adverse features)
         │
         └── Stage II/III (LARC) → Total Neoadjuvant Therapy
                  │
                  ├── CRT → Consolidation chemo (CAPOX/FOLFOX) [preferred for organ preservation]
                  │
                  ├── cCR achieved → Watch-and-Wait (surveillance MRI + endoscopy)
                  │       └── Regrowth (25% at 2 years) → Salvage TME
                  │
                  └── Incomplete response → TME
                           │
                           ├── Platform choice:
                           │   TaTME or Robotic TME (equivalent histopathology)
                           │   > Laparoscopic TME > Open TME
                           │
                           └── Very low/sphincter-involved: ELAPE

New Alternatives to Sutures for Skin Closure

1. Surgical Staples

• Fastest skin closure method - particularly valuable in emergencies and long incisions
• Lower infection rates compared to standard sutures in clean wounds (metal is less reactive than suture material)
• Strong mechanical closure - useful for scalp, trunk, and extremity wounds
• No need for post-closure suture removal visits (disposable applicator)

• Requires a dedicated staple remover at follow-up
• Less precise skin edge eversion than subcuticular sutures
• Cosmetically inferior to subcuticular closure for long-term scar appearance
• Not suitable for face or areas requiring precise eversion
• Can cause "staple marks" if left too long (>7-10 days)

• In cesarean sections in obese women, staples vs. subcuticular suture meta-analysis (PMID: 35688324) showed higher wound disruption/hematoma with staples but comparable infection rates
• In head and neck surgery, a study found staples superior to sutures for neck dissection skin closure with reduced time and no cosmetic difference at 6 months

2. Tissue Adhesives (Cyanoacrylate Glues)

Types

Mechanism

• 2-octyl cyanoacrylate releases formaldehyde as a by-product of polymerization - drives its waterproof film
• Bonds to wet/moist skin via anionic polymerization
• Provides a microbial barrier function as the film seals out bacteria (unlike sutures which create a portal of entry for bacteria)
• Breaks down and sloughs off in 5-10 days as skin sheds

Clinical Evidence

• 126 patients randomized: Dermabond vs. subcuticular suture for post-auricular incisions
• OCA saved 12 minutes per incision
• Superior immediate cosmetic appearance, higher patient satisfaction
• No cases of bleeding, hematoma, infection, or wound separation in the adhesive group

• Dermabond vs. polypropylene suture: adhesive showed comparable wound healing, significantly shorter closure time, higher patient satisfaction

• GLUBRAN Tiss 2 vs. nylon sutures: comparable wound healing complications, significantly faster application

• Adhesive tissue glue vs. suture for port-site closure: glue showed significantly lower infection rates and less pain with equivalent cosmesis at 12 months

• Allergy/sensitivity - prior exposure to 2-octyl cyanoacrylate, acrylates (nail glue, eyelash glue), or formaldehyde products contraindicates use; reactions include allergic contact dermatitis, systemic pruritic erythema
• Not suitable for high-tension wounds or mucosal surfaces
• Avoid in contaminated wounds or over infected tissue
• Do NOT apply to eyelids or deep wounds

Dermabond Prineo System

• Abdominal incisions after laparotomy
• Total joint replacement incisions
• Breast surgery incisions

3. Adhesive Wound Closure Strips

Categories and Products

• Superficial skin lacerations under no tension
• Small excision biopsy sites in low-tension areas
• Post-procedure sites where suture removal would be difficult

4. Mechanical Wound Closure Devices

Key Products and Evidence

• A flexible polyurethane bridge device spanning the wound with adhesive anchor pads
• 89% reduction in wound dehiscence vs. conventional closures in elective breast surgery (p<0.001)
• Study by Panton et al. in reduction mammaplasty: significantly decreased nascent scar area and T-junction dehiscence rates
• Mechanism: mechanomodulation - redistributes mechanical forces away from the suture line

• Velcro-bridged skin closure device
• Eliminated T-junction dehiscence in a Wise-pattern breast reduction study
• Particularly valuable for high-risk wound geometries (T-junctions, Y-junctions) prone to tension necrosis

• Elastic spring-like strips with adhesive anchors; adjustable tension
• Used for orthopedic, abdominal, and breast incisions

• Non-invasive, needle-free closure systems using interdigitating microstructures that grip opposing skin edges

• RCT (2024, PMID: 39041065): 50 patients post-robotic prostatectomy randomized to Xkin vs. staples
• Modified Vancouver Scar Scale (mVSS) scores significantly lower in Xkin group at 12 weeks
• Vascularity and pliability significantly better with Xkin
• Faster closure, no suture removal needed, reduced scarring

• Completely needle-free - no sharps injury risk, patient-friendly
• No suture removal appointment needed
• Tension redistribution reduces dehiscence in high-risk locations
• Can be applied and removed without local anesthesia
• Useful in anticoagulated patients where needle passes risk hematoma

• May not adhere well to irregular surfaces, hair-bearing skin, or excessively moist areas
• Not suitable for high-tension primary closures requiring deep anchoring
• More expensive per unit than sutures

5. Fibrin Sealants and Biological Adhesives

• Tisseel (Baxter) - plasma-derived; gold standard fibrin sealant
• Evarrest (Ethicon) - fibrin/thrombin-impregnated patch
• Tachosil - collagen sponge with thrombin and fibrin coating

• Not a primary skin closure device - used primarily for hemostasis in surgical fields and internal tissue adherence
• Adjunct role: applied over dermal suture line to reinforce closure, promote healing, reduce seroma/hematoma formation in plastic/reconstructive surgery, breast surgery, flap surgery
• Particularly used in microvascular surgery to seal anastomotic suture lines
• Biodegradable - absorbed without foreign body reaction - advantage in contaminated wounds

• Inspired by mussel foot proteins that adhere to wet surfaces via DOPA (3,4-dihydroxyphenylalanine) residues
• Hydrogel adhesives based on catechol chemistry are under active development; some have achieved wet-tissue adhesion strength exceeding fibrin
• Not yet FDA-cleared for routine skin closure

6. Closed-Incision Negative Pressure Wound Therapy (ciNPWT)

• Macrodeformation: reduces wound surface area and dead space
• Microdeformation: mechanical forces at cellular level stimulate proliferation, angiogenesis
• Removes wound exudate and reduces edema at incision edges
• Increases local perfusion (5-fold increase in cutaneous blood flow)
• Provides mechanical protection against contamination
• Stabilizes wound environment against shear forces

• PICO (Smith+Nephew): Single-use, canister-free, portable (-80 mmHg)
• Prevena (KCI/3M): Single-use, -125 mmHg, specifically indicated for closed incision management
• NPWT-i (irrigation): Combines negative pressure with saline irrigation for contaminated closed incisions

• Obese patients (BMI >30) undergoing abdominal/orthopedic surgery
• Diabetic patients
• Patients on immunosuppressants
• Patients with previous SSI
• Large joint arthroplasty
• Emergency laparotomy
• Sternotomy / chest wall surgery
• Sabiston Textbook of Surgery, 11e; Campbell's Operative Orthopaedics, 15e

7. Silk Fibroin and Biodegradable Biomaterial Sutures (Next Generation)

• Natural silk protein with high tensile strength + biocompatibility
• Controlled degradation profile (programmable absorption rate)
• Can be functionalized with:
  • Drug-eluting properties (antibiotics, anti-inflammatories released at wound site)
  • Antibacterial coatings (chitosan, silver nanoparticles)
  • Growth factor delivery (VEGF, FGF to stimulate healing)
  • Electronic/biosensor integration (monitoring wound pH, temperature, moisture in real time)

Comparison Summary

Key Selection Principles (PRS-Global Open 2025 Evidence-Based Recommendations)

1. Deep layered closure remains the foundation - topical alternatives supplement rather than replace deep suturing for full-thickness wounds
2. For superficial closure: silk fibroin strips offer the best evidence for strong adherence with minimal complications
3. Mechanical devices are preferred for high-tension or high-dehiscence-risk closures
4. Caution with 2-octyl cyanoacrylate: screen for acrylate allergy before use; associated with hypersensitivity reactions in sensitized patients
5. ciNPWT should be reserved for high-risk patients (obesity, diabetes, immunosuppression, contaminated field) where evidence of SSI reduction is strongest
6. Plain petrolatum remains the safest topical wound agent - equivalent protection to antibiotic ointments without allergy or resistance risk

Minimally Invasive Surgical Treatment Options for Ventral Hernia (Last Decade)

1. Laparoscopic Intraperitoneal Onlay Mesh (IPOM) - The Original MIS Standard

• Patient placed supine; trocars sited away from the defect (typically left lateral or right lateral)
• Systematic adhesiolysis to free the anterior abdominal wall
• Hernia contents reduced; sac left in situ or partially excised
• Dual-layer (barrier-coated) mesh placed intraperitoneally and fixed with a combination of tacks and/or transfascial sutures, with at least 3-5 cm overlap beyond the defect margins

• Avoids large abdominal wall incision - preserves anterior abdominal wall integrity
• Lower SSI/wound complication rates vs. open repair
• Shorter hospital stay, faster recovery
• Suitable for BMI >30 patients where open wound complications are highest

• Mesh in direct contact with viscera (adhesion risk, fistula, erosion) even with barrier coatings
• Cannot address large defects (>10 cm) or loss of domain
• Higher seroma rate than open retromuscular repair
• Mesh fixation with tacks risks bowel injury, chronic pain
• Mulholland and Greenfield's Surgery 7e, Chapter 72

2. MILOS / eMILOS - Mini or Less-Open Sublay

• A small incision (3-5 cm) is made adjacent to the hernia
• Endoscopic instruments are introduced to create the retromuscular space (posterior to rectus abdominis, anterior to posterior rectus sheath)
• The hernia defect is closed primarily
• A large polypropylene mesh is deployed in the retromuscular space under endoscopic visualization
• No peritoneal entry required (totally extraperitoneal)

• MILOS vs. laparoscopic IPOM cohort study: recurrence rate 2.2% (MILOS) vs. 7.3% (IPOM) (OR 0.28, 95% CI 0.14-0.57)
• Significantly lower complication rate with MILOS
• Lower pain scores at 1 year post-surgery
• (Referenced in EHS/BHS midline incisional hernia guidelines)

• Avoids intraperitoneal mesh (no visceral adhesion risk)
• Retromuscular mesh placement - best biomechanical position
• Preserves abdominal wall physiology
• No foreign body contact with bowel

3. Enhanced View Totally Extraperitoneal (eTEP) - The Emerging Gold Standard

1. Initial access via a small incision lateral to the rectus (usually contralateral to the hernia or caudal to it)
2. Entry into the retromuscular space (posterior to rectus abdominis, anterior to posterior rectus sheath/transversalis fascia)
3. Balloon or direct dissection to develop the retromuscular space
4. "Extended" visualization crosses the midline to develop the bilateral retromuscular space
5. Hernia defect is closed primarily from the posterior aspect
6. Large mesh (typically lightweight polypropylene) placed in the retromuscular space with wide overlap
7. Posterior sheath closed over the mesh

• eTEP Rives-Stoppa: Places mesh in the classical Rives-Stoppa retromuscular position
• eTEP-TAR: Adds Transversus Abdominis Release (TAR) to extend mesh to the preperitoneal space beyond the semilunar line for very large defects
• Robotic eTEP: The da Vinci system's wrist articulation and 3D vision greatly facilitate the posterior sheath closure and precise dissection

• 13 studies, 918 patients (laparoscopic + robotic eTEP)
• SSI rate: 0%
• Seroma: 5%
• Major complications (Clavien-Dindo III-IV): 1%
• Conversion rate: 1%
• Recurrence: 1% at median 6.6 months follow-up
• Mean hospital stay: 1.77 days

• Mesh extraperitoneal - no visceral contact
• Primary defect closure achieved routinely
• Restores abdominal wall biomechanics
• Can be extended with TAR for large defects
• Mulholland and Greenfield's Surgery 7e; Hernia journal meta-analysis 2022

4. Robotic Intraperitoneal Onlay Mesh (rIPOM / rIPOM+)

• Randomized 75 patients (38 laparoscopic IPOM, 37 robotic IPOM)
• 1-year results (PMID: 35703814): Comparable pain, comparable quality of life; robotic had significantly longer operative time
• 5-year results (PMID: 42426391) - published July 2026:
  • HerQLes QoL: 92 (laparoscopic) vs. 92 (robotic) - identical
  • Pain (PROMIS 3a): 31 vs. 31 - identical
  • Clinical recurrence: 10% (laparoscopic) vs. 24% (robotic) - not statistically significant (p=0.27)
  • Reoperation rates comparable

• Robotic IPOM: 62.6 minutes longer operative time (p<0.00001, moderate certainty evidence)
• No significant difference in: complications, hospital stay, readmission, reoperation, conversion, or hernia recurrence at 12-24 months

• Facilitates intracorporeal defect closure (suturing) - critical for the IPOM+ technique
• Less open conversion (PMID: 34557961): OR 0.22 (95% CI 0.09-0.54)
• Better ergonomics for long operations

5. Robotic Retromuscular Repair / Robotic TAR (rTAR)

• Robotic Rives-Stoppa (retromuscular repair): Mesh placed in the retromuscular space
• Robotic TAR: Posterior rectus sheath incised medial to linea semilunaris → transversus abdominis muscle divided → preperitoneal plane entered → bilateral dissection to mid-axillary line → large mesh placed retromuscularly with wide lateral coverage
• Double-dock technique: Required for large midline defects - separate trocar positions used for each side of the abdomen, robot re-docked

• 100 high-risk patients (BMI ≥30, DM, COPD, or smokers; hernia 7-15 cm) randomized: open retromuscular vs. robotic retromuscular
• Primary composite outcome (SSI + SSO + readmission + recurrence): 20.5% open vs. 19.6% robotic - no difference (p=1.000)
• Hospital stay significantly shorter with robotic: 1 day vs. 2 days (p<0.001)
• Significant QoL improvement in both groups at 1 and 2 years
• Conclusion: robotic RMVHR achieves equivalent AWR outcomes with shorter hospital stay

6. Laparoscopic Transabdominal Preperitoneal (TAPP) for Ventral Hernia

• Pneumoperitoneum established; peritoneum incised circumferentially around the defect
• Preperitoneal space developed (between peritoneum and posterior rectus sheath/transversalis fascia)
• Hernia defect closed primarily
• Mesh placed in the preperitoneal space
• Peritoneal flap re-approximated over mesh (isolating mesh from viscera)

• Mesh is extraperitoneal - no visceral adhesion risk
• Peritoneal coverage without extensive retroperitoneal dissection
• Suitable for small to medium defects

7. Endoscopic Component Separation Techniques

Endoscopic Anterior Component Separation (eACS) - Ramirez Technique

• Developed in early 2000s, refined in last decade
• Small incision made lateral to the hernia; endoscope introduced into subcutaneous plane
• External oblique aponeurosis incised from costal margin to inguinal ligament under direct visualization
• Preserves periumbilical perforating vessels (reduces skin necrosis risk vs. open anterior CS)
• Provides 4-8 cm of medialization on each side
• Can be combined with laparoscopic IPOM for reinforcement

Robotic/Laparoscopic Posterior Component Separation (TAR)

• As described in Section 5 - now the preferred form of MIS component separation
• Superior to anterior CS: does not disrupt anterior abdominal wall vasculature; provides 5-10 cm medialization per side; creates large retromuscular mesh pocket

8. Single-Incision / LESS (Laparoendoscopic Single-Site) Repair

• Multi-channel single port placed at umbilicus (or periumbilical)
• Standard laparoscopic instruments used via angled/articulating instruments
• Mesh placed intraperitoneally or defect closed + mesh

9. Natural Orifice Transluminal Endoscopic Surgery (NOTES) - Experimental

• Access via the umbilical hernia sac itself combined with conventional laparoscopic ports
• Primarily used for small umbilical hernias as a scarless approach

Comparative Summary Table

Trend and Current Position

1. Defect closure is now mandatory - bridging repairs have significantly higher recurrence and should be avoided
2. Extraperitoneal mesh (retromuscular/preperitoneal) is preferred over intraperitoneal to eliminate visceral adhesion risk
3. eTEP (laparoscopic or robotic) has emerged as the preferred technique for small-large midline defects when MIS retromuscular repair is desired
4. Robotic platforms enable primary suturing, TAR, and eTEP that previously required open surgery - at the cost of longer operative time and higher cost, with comparable outcomes to both open and laparoscopic repair
5. Patient selection remains key: body habitus, defect size (EHS classification W1 <4 cm, W2 4-10 cm, W3 >10 cm), prior repairs, and wound risk stratification guide technique choice

Recent Advances in Drug Delivery Systems for Enhancing Drug Penetration into Tumors

The Core Challenge: Why Tumors Are Hard to Penetrate

1. Physical barriers: Dense extracellular matrix (ECM) - particularly collagen, fibronectin, hyaluronan in desmoplastic tumors (pancreatic, breast) - physically excludes large particles
2. Elevated interstitial fluid pressure (IFP): Leaky tumor vasculature + poor lymphatic drainage create outward fluid pressure (10-40 mmHg in tumors vs. ~0 mmHg in normal tissue) that opposes convective drug entry
3. Irregular/heterogeneous vasculature: Poorly perfused hypoxic zones receive inadequate drug; distance from vessels to tumor cells may exceed diffusion limits
4. Mononuclear phagocyte system (MPS) clearance: Nanoparticles are recognized and cleared by macrophages in liver/spleen before reaching tumors
5. Tumor microenvironment (TME) immunosuppression: Inhibits drug-carrying immune cells

1. Liposomal Drug Delivery Systems - Evolution of the Clinical Standard

Clinically Approved Liposomal Platforms

Recent Advances in Liposome Technology

• Nanobody-conjugated liposomes: Chimeric nanobody-decorated liposomes self-assemble on tumor cell surfaces (Nat Nanotechnol 2024; TROP2-targeting for pancreatic cancer)
• TROP2-directed nanobody-liposome conjugates: Demonstrated potent antitumor effect in pancreatic cancer
• pH-sensitive liposomes: Lipid composition engineered to destabilize and release payload specifically at tumor pH (~6.5 vs. systemic pH 7.4)
• Thermosensitive liposomes: Release drug upon local hyperthermia (e.g., ThermoDox - lyso-thermosensitive liposomal doxorubicin) - exploits tumor heating to trigger burst drug release

2. Lipid Nanoparticles (LNPs) for Nucleic Acid Cancer Therapy

Structure and Mechanism

Cancer Applications

• Patisiran (Onpattro) - FDA-approved siRNA LNP for TTR amyloidosis; established clinical proof-of-concept for LNP-nucleic acid delivery
• siRNA targeting oncogenes (KRAS, VEGF, HIF-1α, MDR genes like ABCB1) in clinical trials
• siRNA vs. MDR: Disrupt P-glycoprotein (ABCB1) or BCL-2 expression to resensitize drug-resistant tumors

• LNPs encoding tumor neoantigens delivered intramuscularly/intratumorally to elicit CTL responses
• Lyophilizable LNP vaccine (E7 peptide + Mn²⁺ STING agonist) in murine cervical cancer: strong CD8+ T-cell response, prevented tumor recurrence
• BNT111/mRNA-4157 (Moderna/Merck): personalized mRNA neoantigen vaccines in LNPs - Phase 2/3 trials in melanoma + pembrolizumab

• Traditional LNPs target liver (hepatotropism due to ApoE adsorption)
• Selective Organ Targeting (SORT) technology: adding a fifth lipid component with distinct charge/ratio redirects LNPs to lung, spleen, or specific cell types in tumors

3. Polymeric Nanoparticles

PLGA-Based Systems

• PLGA nanoparticles: FDA-GRAS materials; hydrolytic degradation releases drug over days-to-weeks
• Surface functionalization with targeting ligands (folate, transferrin, RGD peptides, antibodies)
• Combination delivery: Co-encapsulate two chemotherapeutics at synergistic ratios (e.g., paclitaxel + cisplatin) - impossible with free drugs due to different PK profiles

Dendrimers

• Highly branched synthetic macromolecules (generations G0-G10) with precise molecular architecture
• PAMAM dendrimers: Internal cavities for hydrophobic drug encapsulation; surface amino groups for conjugation
• Allow drug release triggered by pH, redox state, or enzymatic cleavage at the tumor site
• Multivalent targeting: Multiple surface ligands achieve higher avidity for tumor receptors than monovalent approaches

Polymeric Micelles

• Self-assembling amphiphilic block copolymers (PEG-PLGA, PEG-PCL) that form 10-100 nm micellar structures
• Hydrophobic core encapsulates poorly water-soluble drugs; PEG corona provides stealth properties
• Genexol-PM (paclitaxel polymeric micelle): Approved in South Korea; equivalent efficacy to Cremophor-paclitaxel with reduced toxicity; in US Phase II trials

4. Stimuli-Responsive ("Smart") Nanocarriers

Endogenous Stimuli

• Tumor microenvironment is acidic (pH 6.5-6.8 extracellular; pH 4.5-5.5 in endosomes/lysosomes) due to Warburg effect
• pH-labile linkers (hydrazone, acetal, orthoester bonds) cleave at low pH to release drug
• Acid-responsive charge-reversal nanoparticles: Neutral/negatively charged during circulation → positive charge in acidic TME → enhanced cellular uptake via electrostatic interaction with negative cell membrane

• Tumor cells have 100-1000x higher glutathione (GSH) concentrations than normal tissue
• Disulfide bond-containing linkers are cleaved by GSH → intracellular drug release
• Prodrugs activated only inside tumor cells (minimizes systemic toxicity)

• Tumor hypoxia (<5 mmHg pO₂) activates bioreductive linkers containing nitroimidazole, azobenzene, or quinone groups - cleaved only under low oxygen
• Hypoxia-activated prodrugs (HAPs): e.g., tirapazamine, TH-302 (evofosfamide) - inactive systemically, activated in hypoxic tumor zones
• In PDAC models, hypoxia-responsive systems achieved >2-fold tumor growth inhibition and 60% increase in intratumoral necrosis vs. controls (PMID: 41229675)

• Matrix metalloproteinases (MMPs): MMP-2 and MMP-9 are overexpressed in tumor stroma; MMP-cleavable peptide linkers (e.g., GPLGIAGQ) trigger drug release at the tumor site (PMID: 37533285)
• Cathepsin-B/D: Lysosomal proteases overexpressed in tumor cells - used as the trigger for intracellular release in ADCs (see Section 6)
• Collagenase-loaded nanoparticles degrade the ECM to improve penetration of co-delivered therapeutics (collagenase NPs enhanced drug penetration into pancreatic tumor models - ACS Nano 2019)

• Combined pH + redox, pH + enzyme, or pH + redox + hypoxia triggers - achieve spatial AND temporal specificity
• "AND gate" logic: drug release only when multiple tumor-specific conditions are simultaneously present (PMID: 41480332)

Exogenous Stimuli

• Photoresponsive nanocarriers incorporating azobenzene, spiropyran, or coumarin groups
• NIR irradiation (700-1000 nm, tissue penetration up to ~1 cm) induces conformational change → drug release
• Combined photothermal + drug delivery: gold nanorods/nanostars convert NIR to heat (40-45°C) → triggers thermal-responsive polymer collapse + localized cell death
• Limitation: Penetration depth limits applicability to superficial/endoscopy-accessible tumors

• High-tissue-penetrating X-rays trigger drug release from X-ray-sensitive nanocarriers (nitrobenzyl, coumarin derivatives)
• Can combine with existing radiotherapy fields - the same treatment field triggers drug release (PMID: 37278399)

5. Physical Enhancement Strategies

Focused Ultrasound (FUS) + Microbubbles (Sonoporation)

• Gas-filled microbubbles (1-10 µm diameter; e.g., Definity, SonoVue) circulate with IV-administered drug or nanoparticle
• FUS application causes microbubble stable cavitation (oscillation) or inertial cavitation (collapse) at the focal zone
• Mechanical effects: transient pore formation in cell membranes (sonoporation), increased vascular permeability, disruption of tight junctions, ECM remodeling
• Net effect: up to 10-fold increase in intratumoral drug concentration vs. passive delivery
• Pancreatic cancer (Review, Cancers 2026, PMID: 41749827): FUS disrupts the desmoplastic stroma of PDAC, the primary barrier to chemotherapy delivery - one of the most promising strategies for this otherwise treatment-refractory cancer

• Focused ultrasound + microbubbles is the only non-invasive method to reversibly open the BBB
• Phase I/II clinical trials (SonoCloud-9 implantable transducer; ExAblate Neuro, InSightec): demonstrated safe, reproducible BBB opening in glioblastoma patients
• Allows delivery of chemotherapy (carboplatin, doxorubicin, bevacizumab) to brain tumors at concentrations previously impossible

Electroporation / Electrochemotherapy

• High-voltage pulsed electric fields transiently permeabilize cell membranes in tumors
• Combined with bleomycin or cisplatin - electrochemotherapy (ECT): approved in EU for skin/subcutaneous tumors
• Irreversible electroporation (IRE)/NanoKnife: ablates tissue without thermal damage; clinical use in pancreatic/liver tumors

6. Antibody-Drug Conjugates (ADCs) - Targeted Precision Delivery

Structure and Components

• Antibody: High-specificity mAb targeting tumor-associated antigens (TAAs) expressed on cancer cells
• Linker: Cleavable (cathepsin-B, MMP, disulfide, pH-sensitive) or non-cleavable; controls where/when payload releases
• Payload (warhead): Highly potent cytotoxins - 100-1000x more potent than conventional chemotherapy; examples: MMAE (auristatin), DM1/DM4 (maytansinoids), DXd (camptothecin derivative), PBD dimers
• Drug-antibody ratio (DAR): Typically 2-8 drug molecules per antibody; determines potency vs. tolerability

Clinically Approved ADCs (as of 2025: 15 FDA-approved)

Recent Innovations in ADC Design (PMID: 41033317)

1. Site-specific conjugation: Thiol-maleimide chemistry replaced by transglutaminase, click chemistry (SPAAC), or unnatural amino acid incorporation for homogeneous DAR - improves PK and therapeutic index
2. TME-responsive linkers: MMP-cleavable, cathepsin-B-activatable linkers release drug only inside tumor cells or tumor stroma
3. Bispecific ADCs: Antibody targets two antigens simultaneously - addresses tumor heterogeneity and antigen escape
4. Probody masking: Protease-cleavable mask on antibody binding site → ADC is inactive systemically, activated by tumor-specific proteases (e.g., uPA, MMP) only in TME
5. Immune-stimulating ADCs (ISACs): Payloads trigger immunogenic cell death (TLR agonists, STING agonists) in addition to direct cytotoxicity - convert "cold" to "hot" tumors
6. Degrader-ADCs (DACs): Payload is a PROTACs (proteolysis-targeting chimeras) that degrades oncoproteins catalytically
7. Bystander effect: Membrane-permeable payloads (MMAE, DXd) diffuse from ADC-targeted cells to kill adjacent antigen-negative tumor cells - critical for heterogeneous tumors

7. Biomimetic / Cell Membrane-Coated Nanoparticles

Types of Membrane Coatings

Exosomes

• Endogenous extracellular vesicles (30-150 nm) released by cells
• Naturally carry proteins, lipids, miRNA between cells
• Key advantages: High biocompatibility, minimal immunogenicity, intrinsic deep tissue penetration capability, natural BBB crossing
• Loaded with doxorubicin, paclitaxel, siRNA, miRNA for tumor delivery
• iRGD-functionalized dendritic cell-derived exosomes loaded with doxorubicin: efficient tumor accumulation, significant tumor suppression in glioma models
• Plant-derived exosomes: Grape, ginger, grapefruit-derived exosomes - scalable, low immunogenicity, oral delivery potential
• Nat Rev Clin Oncol 2023 (Fang, Gao, Zhang): Cell membrane-coated nanoparticles as a transformative platform for tumor targeting

Bacterial/Microbiome-Based Delivery

• Bacteria naturally accumulate in hypoxic tumor cores (which nanoparticles cannot reach)
• Engineered bacteria (e.g., E. coli Nissle, Salmonella attenuated strains) used as self-propelled "micro-robots" delivering:
  • Cytotoxins
  • Prodrug-activating enzymes (Nat Commun 2025: NP delivery of a prodrug-activating bacterial enzyme → anti-tumor responses)
  • siRNA/miRNA payloads
• Tumor-specific promoters activate payload expression only in the hypoxic tumor microenvironment

8. ECM-Targeting and Tumor Stroma Modulation

Strategies

• Collagenase/hyaluronidase co-loaded nanoparticles: degrade collagen and hyaluronic acid → reduce IFP, improve penetration of co-delivered drugs (demonstrated in PDAC models - ACS Nano 2019)
• Detachable dual-targeting NPs: first target ECM components for degradation, then target tumor cells (ACS Biomater Sci Eng 2023)

• Losartan (AT1R antagonist): reduces collagen synthesis → improves nanomedicine penetration; in clinical trials combined with FOLFIRINOX for pancreatic cancer

• PEGPH20 (pegylated hyaluronidase): enzymatically depletes hyaluronan from tumor stroma; Phase II trials in PDAC and breast cancer (mixed results - excess bleeding with gemcitabine in PDAC, new trials ongoing)

• Anti-VEGF agents (bevacizumab): "vascular normalization" theory - rather than destroying tumor vessels, normalize their structure → reduce IFP, improve perfusion, enhance drug delivery window (Jain's normalization hypothesis)

9. RNA Therapeutics and Gene Delivery Platforms

• LNP-encapsulated siRNA silences oncogene expression at the mRNA level
• Targets: KRAS (most common oncogene; KRAS G12C inhibitors now combined with siRNA for G12D/G12V), VEGF, HIF-1α, MDR1
• Nanotechnology-enhanced siRNA delivery: polymer-lipid hybrid NPs, dendrimer complexes, exosome delivery (PMID: 40354673)

• LNPs deliver mRNA encoding tumor-specific neoantigens → activate cytotoxic T lymphocytes (CTL)
• mRNA-4157 (Moderna) + pembrolizumab: Phase 3 trial in resected high-risk melanoma (KEYNOTE-942) - reduced recurrence vs. pembrolizumab alone; a landmark personalized cancer vaccine trial

• LNPs and nanoparticles deliver CRISPR components to edit oncogenes or immunosuppressive genes in tumor-infiltrating lymphocytes
• In vivo editing of PD-1 in T cells, disruption of cancer-promoting genes in tumor cells
• Multiple Phase I trials underway

10. Artificial Intelligence-Guided Drug Delivery Design

• Machine learning for nanoparticle optimization: Predict nanoparticle size, surface charge, composition combinations that maximize tumor accumulation and minimize systemic clearance
• AI-guided ADC design: Identify optimal target antigens, linker types, and DAR ratios by modeling tumor heterogeneity data
• In silico prediction of tumor-specific accumulation: Structure-function relationships for hypoxia-responsive NPs predicted computationally, reducing animal testing burden
• Digital twin models: Patient-specific tumor pharmacokinetic simulations to optimize dosing of nanomedicines

Summary: Hierarchy of Current Approaches

Stereotactic Surgery: Principles and Applications

Definition and Concept

Historical Development

Core Principles

1. The Three-Dimensional Coordinate System

• X-axis: Mediolateral (left-right)
• Y-axis: Anteroposterior (front-back)
• Z-axis: Superoinferior (up-down)

2. The Stereotactic Frame (Reference System)

• Rigidly fixed to the skull (via pins/screws under local anaesthesia) - ensuring no movement between imaging and surgery
• Radiopaque - visible on CT and MRI so that fiducial markers on the frame appear as reference points in imaging
• Geometrically precise - its own coordinate system is defined to sub-millimetre accuracy

1. Base ring: Fixed to skull with 4 pins; establishes the coordinate origin
2. Fiducial box/localizer: Attached during imaging; contains radiopaque rods at known positions
3. Arc-centred system: An arc and bow assembly that, when set to calculated coordinates, directs any instrument toward the same isocentric target point from any trajectory angle

3. Imaging and Target Localization

• CT or MRI performed with the stereotactic frame + fiducial box in place
• Fiducial markers in the box appear as predictable geometric patterns on each imaging slice
• Planning software calculates the exact frame coordinates of the target from its position relative to these fiducials
• Accuracy: Sub-millimetre targeting error (~1 mm radial error); gold standard for accuracy

• CT: Best for bony landmarks, fiducial localization, calcifications; less soft tissue contrast
• MRI: Superior soft tissue definition; identifies deep nuclei (subthalamic nucleus, globus pallidus, ventral intermediate nucleus of thalamus), tumour margins, vascular structures
• CT+MRI fusion: Combines geometric precision of CT with soft tissue detail of MRI - standard for functional neurosurgery
• DSA (digital subtraction angiography) fusion: For vascular targets (AVM, cavernoma)
• fMRI/DTI: Functional MRI and diffusion tensor imaging for eloquent cortex and white matter tract mapping

4. The AC-PC Reference Line

• A horizontal line connecting the AC (anteriorly) and PC (posteriorly) defines the standard orientation plane
• All subcortical target coordinates in brain atlases (Schaltenbrand-Wahren, MNI atlas) are defined relative to the midpoint of this line
• Standard target coordinates for common procedures:
  • STN (subthalamic nucleus): ~12 mm lateral, 3 mm posterior, 4 mm inferior to AC-PC midpoint
  • GPi (globus pallidus internus): ~20-21 mm lateral, 2-3 mm anterior, 4-6 mm inferior to AC-PC midpoint
  • VIM (ventral intermediate nucleus of thalamus): ~11-14 mm lateral, at PC, 0 mm inferior

5. Microelectrode Recording (MER) - Physiological Confirmation

• A fine tungsten microelectrode (tip diameter ~10 µm) records single-unit neuronal firing patterns as it advances through the brain
• Each deep nucleus has a characteristic electrophysiological signature (firing rate, pattern, responses to sensorimotor stimulation)
• STN: High-frequency (40-60 Hz), irregular bursting neurons; sensorimotor neurons respond to contralateral limb movement
• This confirms the electrode is in the correct nucleus before committing to implantation

Systems of Stereotaxy

Frame-Based Stereotaxy

• Mechanical linkage between frame and instrument - highest spatial accuracy (~0.5-1 mm)
• Frame applied on morning of surgery under local anaesthesia
• Standard for DBS, ablative procedures, functional neurosurgery
• Disadvantage: Cumbersome, requires awake frame application, single-session limitation

Frameless Stereotaxy (Neuronavigation)

• No head frame; instead, surface fiducials (adhesive skin markers or implanted bone markers) or surface contouring (laser or structured light) register the patient's anatomy to preoperative imaging
• Infrared cameras track a reflective marker array mounted on instruments in real time
• Workstation displays instrument position within 3D CT/MRI reconstruction
• Accuracy: ~2-3 mm (less accurate than frame-based due to brain shift)
• Advantages: Applicable throughout entire surgery; no frame; allows awake craniotomy guidance; usable for spinal procedures
• Brain shift problem: As CSF drains or tumour is removed during surgery, brain tissue shifts from its preoperative position - frameless navigation becomes less accurate over time; intraoperative MRI or ultrasound updates can compensate

Robotic Stereotaxy

• Robotic arms (ROSA Robot, NeuroMate, RENISHAW neuromate, Mazor Renaissance) execute precisely planned trajectories
• Registered to patient via frame-based or frameless fiducials + intraoperative imaging
• Advantages over manual: Eliminates hand tremor; allows multiple sequential trajectories (SEEG electrode placement); consistent accuracy across all trajectories; fatigue-independent
• Meta-analysis 2024 (PMID: 39615014): Robot-assisted vs. manually guided stereotactic biopsy - robots showed comparable diagnostic yield with potentially lower complications
• Mean radial error for robotic DBS: ~1.24 mm (comparable to frame-based)

Applications

I. Stereotactic Brain Biopsy

• Deep-seated (thalamus, basal ganglia, brainstem, corpus callosum)
• Surgically inaccessible without unacceptable morbidity
• In patients not fit for open craniotomy
• Multi-focal lesions requiring sampling without major surgery

1. Frame applied; CT/MRI performed with fiducial box
2. Planning: trajectory calculated to avoid sulcal vessels, ventricles, eloquent cortex
3. Small burr hole (14 mm); side-cutting biopsy needle advanced to target coordinates
4. Multiple cores obtained from different positions within target
5. Diagnostic yield: 90-95% for most lesions; lower for necrotic centres (hence targeting enhancing rim)

• 5-ALA (aminolevulinic acid) accumulates in glioma tissue → fluoresces under violet light
• Sodium fluorescein also used
• Systematic review (PMID: 39126591): fluorescence guidance improves sampling accuracy in heterogeneous high-grade gliomas

• Stereotactic biopsy vs. endoscopic biopsy vs. neuronavigation-guided biopsy debated
• Systematic review 2026 (PMID: 42115459): comparative analysis ongoing; each approach has specific indications depending on anatomy and associated hydrocephalus

II. Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT)

Radiobiological Principle

• Conventional radiotherapy delivers 1.8-2 Gy per fraction over 30-40 fractions (total 50-70 Gy)
• SRS delivers 12-25 Gy in a single fraction (or 3-5 fractions in fractionated SRS)
• The steep dose fall-off at the target margin (achieved by multiple convergent beams) is critical - dose drops from therapeutic to negligible within 2-3 mm of the target edge
• Mechanism: Direct DNA double-strand breaks; vascular injury → obliteration of tumour vessels; immunogenic cell death (abscopal effects when combined with immunotherapy)

Devices

• 192 Cobalt-60 sources arranged in a hemispherical helmet; all beams converge at a single isocenter
• Frame-based; highest intracranial accuracy (<0.5 mm)
• Gold standard for small intracranial targets
• Over 1,000,000 patients treated worldwide since 1968
• Icon model (2015-present): Added mask-based frameless option; allows fractionated SRS

• Compact 6-MV LINAC mounted on a robotic arm (KUKA robot)
• Frameless; uses real-time image guidance (X-ray pairs) with respiratory tracking
• Can treat both intracranial AND extracranial targets
• Hypofractionation of 1-5 fractions

• Standard medical LINAC modified with micro-multileaf collimator (MLC) for stereotactic precision
• Multiple arcs or volumetric modulated arc therapy (VMAT) create pseudo-spherical high-dose volumes
• Most widely available platform

• Real-time MRI guidance during radiation delivery
• Adaptive re-planning within session as anatomy changes
• Emerging for both intracranial and extracranial SRS/SBRT

SRS Indications and Evidence

• SRS is the cornerstone of management for 1-4 brain metastases (oligometastatic disease)
• Nature Reviews Clinical Oncology 2025 (PMID: 40108412): recent advances include:
  • Polymetastatic SRS (>4 metastases): Multiple randomized trials (JLGK0901, Alliance A071801) show SRS feasible and effective for 5-10+ metastases with comparable outcomes to WBRT (whole brain radiotherapy) and superior neurocognitive preservation
  • Preoperative SRS: Irradiate tumour before surgical resection → sterilizes surgical margins, reduces leptomeningeal dissemination risk, higher-dose delivery possible
  • Fractionated SRS (fSRS): 3-5 fraction SRS for large metastases (>3 cm) or proximity to optic apparatus/brainstem - reduces radiation necrosis risk vs. single-fraction
  • SRS + immunotherapy/targeted therapy: Synergistic responses; checkpoint inhibitors (pembrolizumab, nivolumab) appear to enhance SRS response (abscopal effect data)

• SRS causes progressive obliteration of AVM nidus via radiation-induced thrombosis and vessel wall fibrosis over 2-4 years
• Obliteration rates: ~80-85% for small AVMs (<3 cm) at 3-5 year follow-up
• Annual bleed risk remains until obliteration is complete

• SRS (typically Gamma Knife) for tumours <2.5-3 cm
• Tumour control rate: >90% at 10 years
• Hearing preservation: ~50-60%
• Facial nerve function preservation: >95%

• Excellent local control (~95% at 5 years) for skull base meningiomas where surgery carries high morbidity

• SRS for residual or recurrent secreting adenomas; normalizes hormonal hypersecretion in 40-70% depending on type

• Gamma Knife radiosurgery to the trigeminal nerve root entry zone
• Pain response: 80-90% initial; maintained in ~55-60% at 3 years
• Mechanism: partial axonal conduction block

• Gamma Knife thalamotomy (VIM target) for essential tremor - non-invasive ablation
• Pain relief for various pain syndromes

Stereotactic Body Radiotherapy (SBRT) - Extracranial

• SBRT has replaced surgery as preferred treatment for medically inoperable early-stage NSCLC
• Local control: >90% at 3 years; comparable to surgery in population-matched analyses

• Prostate cancer: Systematic review/meta-analysis 2024 (PMID: 39690404): SBRT as metastasis-directed therapy in oligometastatic prostate cancer - improved PFS, delayed need for systemic treatment
• Liver, spine, adrenal, lymph node metastases: Local control rates 85-95%

• High-precision radiation to vertebral body tumours with spinal cord sparing
• Local control: ~85% at 2 years for spinal metastases

III. Deep Brain Stimulation (DBS)

Components

1. Lead: Thin electrode (1.27 mm diameter) with 4-8 contact points; implanted in the target nucleus
2. Extension wire: Subcutaneous cable from lead to IPG
3. IPG (implantable pulse generator / neurostimulator): Battery-powered device implanted in infraclavicular chest wall; delivers programmable stimulation

Mechanism

Targets and Indications

• Traditional DBS performed awake to allow MER and intraoperative testing
• Advances in high-resolution MRI targeting + intraoperative CT verification allow asleep DBS (under general anaesthesia) with comparable accuracy
• New stereotactic systems (e.g., skull-mounted key systems, 2024 [JNS paper]): Mean radial error ~1.24 mm in asleep single-stage DBS - enables combined single-stage cranial lead + IPG insertion

• DBS: Reversible, adjustable, bilateral possible, more complex hardware
• Ablation (thalamotomy/pallidotomy): Permanent, no hardware, lower cost, suitable when DBS compliance is an issue

IV. Stereotactic Ablation

Radiofrequency Ablation (RFA) / Thermocoagulation

• Stereotactically placed RF electrode delivers 80-85°C heat → protein denaturation and tissue coagulation
• Creates a predictable spherical lesion (~3-5 mm diameter)
• Thalamotomy (VIM): For essential tremor; unilateral only (bilateral has high dysarthria/dysphagia risk)
• Pallidotomy (GPi): For PD dyskinesia; largely replaced by DBS but still used in resource-limited settings
• Cingulotomy: For OCD and chronic pain; thermal lesion in anterior cingulate cortex

MR-Guided Focused Ultrasound (MRgFUS) Thalamotomy

• 1024 ultrasound transducer elements arranged in a hemispherical helmet
• All beams converge at a single focal point in the brain
• Temperature rises to 55-60°C at focus → precise thermal ablation
• Real-time MRI thermometry monitors temperature distribution to prevent off-target heating

• Essential Tremor: RCT showed 47% improvement in hand tremor at short-term; benefits sustained long-term; FDA-approved (2016)
• PD tremor: Significant short-term improvement; long-term durability still being established
• Bilateral staged MRgFUS for ET: safe, effective on second side
• Adverse effects: Gait disturbance, paresthesias (common early, subside over time); dysarthria, ataxia (less common)
• Key limitation: Skull density ratio (SDR) - patients with low SDR (dense skull) have inadequate ultrasound penetration - excludes ~30% of candidates

Laser Interstitial Thermal Therapy (LITT)

1. Stereotactic planning and trajectory calculation
2. Small twist-drill craniostomy (3.2 mm)
3. Laser applicator placed at target under MRI guidance
4. Real-time MRI thermometry creates thermal damage threshold maps
5. Surgeon monitors ablation zone on MRI workstation and stops when target is covered

• Recurrent glioblastoma: Overall survival improvement up to 26 months in treated patients
• Radiation necrosis: Faster steroid cessation vs. medical management; avoids open craniotomy
• Mesial temporal lobe epilepsy (MTLE): Seizure-freedom rates comparable to anterior temporal lobectomy with potentially better neuropsychiatric outcomes (language, memory preservation)
• Hypothalamic hamartoma: Seizure reduction in gelastic epilepsy
• Brain metastases (recurrent): Useful in post-SRS recurrence or radionecrosis

V. Stereotactic SEEG (Stereoelectroencephalography)

• Electrodes placed via small 2.5 mm twist-drill craniostomies (no craniotomy)
• Cover a 3D volume of the epileptogenic zone and propagation pathways
• Record ictal and interictal activity; electrical stimulation maps eloquent areas
• After recording (7-21 days), electrodes removed; if resection planned, LITT or open surgery proceeds

• No craniotomy; less infection risk
• Deeper structures accessible (amygdala, hippocampus, insula, opercula, cingulate)
• Better for bilateral investigation

VI. Stereotactic Drug Delivery and Convection-Enhanced Delivery (CED)

• Convection-enhanced delivery (CED): Bulk flow of fluid through a stereotactically placed catheter; distributes agents over a large volume
• Applications: Direct chemotherapy to glioblastoma (IL-13-PE38QQR, HSPPC-96 vaccine), neurotrophic factors (GDNF for Parkinson's)
• Ommaya reservoir: Stereotactically placed ventricular catheter for intrathecal chemotherapy
• Gene therapy vectors (AAV) for neurological disorders delivered via stereotactic CED (ongoing trials for Parkinson's, Huntington's, lysosomal storage diseases)

Accuracy, Errors, and Quality Assurance

Comparison of Stereotactic Approaches

Emerging Frontiers

1. Closed-loop DBS: Adaptive neurostimulators that sense neural biomarkers (beta power) and adjust stimulation parameters in real time - delivered only when pathological activity is detected, reducing power consumption and side effects (Medtronic Percept PC with BrainSense technology)
2. Augmented reality (AR) in stereotaxy: Head-mounted displays project stereotactic navigation data directly onto the surgeon's visual field - reduces need for screen-based neuronavigation
3. AI-based target identification: Deep learning algorithms automatically segment deep brain nuclei on MRI, reducing the skill dependence of target identification
4. AMIGO suite (Advanced Multimodality Image-Guided Operating Room, Harvard): Integrates 3T intraoperative MRI + PET/CT + stereotactic navigation + operating microscope in a single suite, enabling real-time imaging verification and adaptive planning during surgery
5. Focused ultrasound beyond tremor: MRgFUS pallidotomy for PD (FDA approved 2023), MRgFUS for OCD, depression, and thalamic pain - expanding the non-invasive ablation portfolio
6. Transcranial MRI-guided focused ultrasound (tcMRgFUS) drug delivery: Opening the BBB focally with low-intensity FUS + microbubbles under MRI guidance to deliver chemotherapy or immunotherapy to brain tumours - Phase I/II clinical trials